Results 1 to 10 of about 1,338,990 (167)

Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma

Nature Communications, 2021
The gut microbiota is reported to modulate the immune response in hepatocellular carcinoma (HCC). Here, we employ metagenomic and metabolomic studies to characterise gut microbiota in patients with non-alcoholic fatty liver disease (NAFLD) related ...
J. Behary, N. Amorim, Xiao-Tao Jiang, A. Raposo, L. Gong, E. McGovern, Ragy Ibrahim, F. Chu, C. Stephens, H. Jebeili, V. Fragomeli, Y. Koay, M. Jackson, J. O’Sullivan, M. Weltman, G. McCaughan, E. El-Omar, A. Zekry   +17 more
semanticscholar   +1 more source

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Journal of Clinical Oncology, 2020
PURPOSE The immunomodulatory effect of lenvatinib (a multikinase inhibitor) on tumor microenvironments may contribute to antitumor activity when combined with programmed death receptor-1 (PD-1) signaling inhibitors in hepatocellular carcinoma (HCC).
R. Finn, M. Ikeda, A. Zhu, M. Sung, A. Baron, M. Kudo, T. Okusaka, M. Kobayashi, H. Kumada, S. Kaneko, M. Pracht, K. Mamontov, T. Meyer, T. Kubota, C. Dutcus, Kenichi Saito, A. Siegel, L. Dubrovsky, K. Mody, J. Llovet   +19 more
semanticscholar   +1 more source

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

New England Journal of Medicine, 2018
BACKGROUND Cabozantinib inhibits tyrosine kinases, including vascular endothelial growth factor receptors 1, 2, and 3, MET, and AXL, which are implicated in the progression of hepatocellular carcinoma and the development of resistance to sorafenib, the ...
G. Abou-Alfa, T. Meyer, A. Cheng, A. El-Khoueiry, L. Rimassa, B. Ryoo, I. Çiçin, P. Merle, Yen-Chang Chen, Joong-Won Park, J. Blanc, L. Bolondi, H. Klümpen, S. Chan, V. Zagonel, T. Pressiani, M. Ryu, A. Venook, C. Hessel, A. Borgman-Hagey, G. Schwab, R. Kelley   +21 more
semanticscholar   +1 more source

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

JAMA Oncology, 2020
Key Points Question Does adding ipilimumab to nivolumab improve clinical outcomes for patients with advanced hepatocellular carcinoma previously treated with sorafenib?
T. Yau, Yoon-Koo Kang, Tae-You Kim, A. El-Khoueiry, A. Santoro, B. Sangro, I. Melero, M. Kudo, M. Hou, A. Matilla, F. Tovoli, J. Knox, A. Ruth He, B. El-Rayes, M. Acosta-Rivera, Ho Yeong Lim, J. Neely, Yun Shen, T. Wisniewski, Jeffrey Anderson, Chiun Hsu   +20 more
semanticscholar   +1 more source

The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects

Signal Transduction and Targeted Therapy, 2020
Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC), sorafenib is currently an effective first-line therapy. Unfortunately,
Weiwei Tang, Ziyi Chen, Wenling Zhang, Ye Cheng, Betty Zhang, Fan Wu, Qian Wang, Shouju Wang, D. Rong, F. Reiter, E. Toni, Xuehao Wang   +11 more
semanticscholar   +1 more source

Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)

Liver Cancer, 2020
Background: Primary liver cancer, around 90% are hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people.
Jian Zhou, Huichuan Sun, Zheng Wang, W. Cong, Jian-hua Wang, M. Zeng, Weiping Zhou, P. Bie, Lian-Xin Liu, T. Wen, G. Han, Maoqiang Wang, Ruibao Liu, Ligong Lu, Zheng-Gang Ren, Minshan Chen, Z. Zeng, P. Liang, C. Liang, Min Chen, Fuhua Yan, Wenping Wang, Yuan Ji, J. Yun, Dingfang Cai, Yongjun Chen, W. Cheng, Shuqun Cheng, C. Dai, Wenzhi Guo, B. Hua, Xiaowu Huang, W. Jia, Yaming Li, Yexiong Li, Jun Liang, Tianshu Liu, Guoyue Lv, Y. Mao, T. Peng, W. Ren, Hongcheng Shi, G. Shi, K. Tao, Wentao Wang, Xiaoying Wang, Zhiming Wang, Bangde Xiang, B. Xing, Jianming Xu, Jiamei Yang, Jian-yong Yang, Yefa Yang, Yunke Yang, S. Ye, Zhengyu Yin, Bixiang Zhang, Boheng Zhang, Leida Zhang, Shuijun Zhang, Ti Zhang, Yong-fu Zhao, Honggang Zheng, Jiye Zhu, K. Zhu, Rong Liu, Yinghong Shi, Yong-Sheng Xiao, Z. Dai, G. Teng, J. Cai, Weilin Wang, Xiujun Cai, Qiang Li, F. Shen, S. Qin, Jiahong Dong, Jia Fan   +77 more
semanticscholar   +1 more source

Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma

Journal of experimental & clinical cancer research : CR, 2020
Liver cancer has become the sixth most diagnosed cancer and the fourth leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) is responsible for up to 75–85% of primary liver cancers, and sorafenib is the first targeted drug for advanced
Jiao Feng, Jingjing Li, Liwei Wu, Qiang Yu, J. Ji, Jianye Wu, Wei-qi Dai, Chuanyong Guo   +7 more
semanticscholar   +1 more source

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

Hepatology International, 2017
There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one of the leading public health problems.
M. Omata, A. Cheng, N. Kokudo, M. Kudo, J. Lee, J. Jia, R. Tateishi, K. Han, Y. K. Chawla, S. Shiina, W. Jafri, D. Payawal, Takamasa Ohki, S. Ogasawara, Pei‐Jer Chen, C. R. Lesmana, L. Lesmana, R. Gani, S. Obi, A. Dokmeci, S. Sarin   +20 more
semanticscholar   +1 more source

Combination immunotherapy for hepatocellular carcinoma.

Journal of Hepatology, 2023
L. Rimassa, R. Finn, B. Sangro
semanticscholar   +1 more source

Hepatocellular Carcinoma: a Narrative Review on Current Knowledge and Future Prospects

Current Treatment Options in Oncology, 2023
Basil Alawyia, C. Constantinou
semanticscholar   +1 more source